Futuro del CRPC. Visión 360º

9 / 28

Tumour burden and activity
Time
NATURAL HISTORY OF PROSTATE CANCER
Hormono-sensitive Castrate-Resistant
Death
Asymptomatic Symptomatic
Metastatic disease NON-Metastatic disease